Acne Severity Endpoints for Clinical Trials
Automated inflammatory lesion counting, spatial density measurement, and IGA scoring for acne clinical trials. AI-powered endpoints aligned with FDA guidance.
Automated inflammatory lesion counting, spatial density measurement, and IGA scoring for acne clinical trials. AI-powered endpoints aligned with FDA guidance.
Performance validation of acne severity endpoints, covering how the ground truth is established, what the metrics mean, ALADIN vs. dermatologist agreement, lesion detection performance, and the regulatory evidence pathway.
End-to-end clinical trial workflow for acne severity endpoints, covering protocol design, patient enrollment, image capture, AI scoring, severity tracking, data export, EDC integration, and decentralised trial support.
Image capture protocols for acne clinical trials, covering smartphone-based photography, DIQA quality control, multi-perspective flexibility, facial landmark detection, and site standardisation.
Transparent documentation of what the AI acne severity scoring can and cannot do, including scope boundaries, validation gaps, and how each limitation is managed.
Peer-reviewed publications, conference presentations, key references from the dermatology literature, and the complete clinical validation portfolio supporting acne severity endpoints.
Concrete examples of what sponsors, CROs, and investigators receive from acne severity assessments: per-visit AI reports with lesion detection overlays, longitudinal severity tracking, and structured EDC data exports.
Technical deep dive into the acne scoring pipeline, covering inflammatory lesion detection, spatial density computation, IGA calculation, ALADIN composite, multi-perspective scoring, overlap handling, and reproducibility.